A members network for financial professionals and private investors. We keep our eyes focused on Nordic Tech and Life Science based companies with global reach.
Joined June 2010
- Tweets 22,069
- Following 254
- Followers 14,526
- Likes 768
13,219 Photos and videos
Redeye comments on Magle announcing an update on the ongoing negotiations with its principal bondholders regarding a comprehensive refinancing and balance sheet restructuring.
$MAGLE
redeye.se/research/1172135/m…
695
Redeye comments on Xbrane partnering with California-based CDMO JOINN Biologics to advance CMC development of Xdarzane, its preclinical daratumumab biosimilar.
$XBRANE
redeye.se/research/1172089/x…
578
Redeye comments on Alzinova announcing today the successful outcome of the TO4 warrant exercise, completing the bridging financing package initiated with the rights issue earlier this year.
$ALZ
redeye.se/research/1172124/a…
1
593
Redeye has interviewed AAC’s CEO, Luis Gomes, following recent progress on the INFLECION program. We discussed the scope, addressed some details and the constellation's future potential.
$AAC
redeye.se/research/1172087/a…
494
Redeye reviews BioInvent’s second key opinion leader (KOL) event of 2026, highlighting clinical development updates for its two lead blood cancer candidates, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB).
$BINV
redeye.se/research/1172082/b…
1
496
Redeye has interviewed Better Collective’s CEO Jesper Søgaard and Gavin Moore who is head SVP of Paid Media.
$BETCO
redeye.se/research/1172077/b…
497
Nanologica is trading below Redeye's Base Case. We spoke with our analyst about what Syntagon is, and why Nanologica acquired it, what would cause Nanologica to require another equity raise, and other key topics.
This is a premium article, included in our paid plans from SEK 99/month.
$NICA
redeye.se/research/1171882/n…
556
Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) for Camurus.
$CAMX
redeye.se/research/1171924/c…
730
Redeye provides its Q1 2026 update for the Swedish Quality Microcap theme.
Theme reports are part of our premium offering, starting at SEK 349/month.
Read the theme report:
redeye.se/research/1171743/r…
676
Redeye has interviewed VEF’s CEO, Dave Nangle. We discuss highlights from the company’s Q1 report, Creditas momentum, the latest developments in Konfío & Juspay and key focus areas for VEF in the coming quarters.
$VEF
redeye.se/research/1171862/v…
558
Redeye has raised its forecasts for Systemair on the back of an upbeat Q4 report.
$SYSR
redeye.se/research/1171811/s…
1
623
Redeye has interviewed Cantargia's CEO Hilde Steineger to discuss what the company will prioritise with the funds from the rights issue, focusing in particular on pancreatic cancer and the paradigm shift with daraxonrasib.
$CANTA
redeye.se/research/1171856/c…
675
Redeye updates on Xspray following a management call that provided some clarification on the Nilopki CRL.
$XSPRAY
redeye.se/research/1171231/x…
611
Redeye har nyligen inlett bevakning av Intervacc och har intervjuat bolagets vd Carl-Johan Dalsgaard.
$IVACC
redeye.se/research/1171389/i…
1
645
Redeye Saas Theme event last out!
13.40 Flowscape – Fredrik Landberg, CEO
14.00 Freja eID – Johan Henrikson, CEO
14.20 Modelon – Jan Häglund, CEO
Tune in:
redeye.se/events/1143975/red…
484
Redeye Saas Theme event is progressing!
12.19 Carasent – Daniel Öhman, CEO
12.31 NordHealth Alexander Cram, CFO
12.43 Physitrack Henrik Molin, CEO
12.55 Panel discussion: Carasent, NordHealth & Physitrack
Tune in:
redeye.se/events/1143975/red…
608
Redeye comments on the new investigator-sponsored phase II study in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer. This is a large market opportunity.
$CANTA
redeye.se/research/1171666/c…
502
Redeye was quite surprised by the strong growth in Q4, almost 10% organically. Earnings were impacted by some non-recurring costs, but reported EBIT of SEK251m was still higher than we expected.
$SYSR
redeye.se/research/1171519/s…
608